Amgen loses battle with Colorado over prescription drug affordability board

admin
3 Min Read

Summarize this content to 100 words In a blow to the pharmaceutical industry, a U.S. court judge ruled that a Colorado state board can proceed with plans to place limits on the prices paid for medicines, the first such decision to support the controversial attempts by some states to control their prescription drug spending.

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to create a so-called upper payment limit. This would establish a payment ceiling for residents who are covered by a government agency or a commercial health plan.

Amgen, however, argued that the board is unconstitutional because its actions conflict with federal law and would regulate business outside of Colorado, among other issues. The company further contended that the board wants to “impose arbitrary price controls” on the sale of drugs — an argument taken up by the pharmaceutical industry, at large — and would also “strip away” intellectual property rights.

STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.
Subscribe

window.statGlobal = window.statGlobal || { };
window.statGlobal.analytics = window.statGlobal.analytics || { };

window.statGlobal.analytics.fbq = function( eventName, parameters ) {
jQuery.ajax( {
url: ‘/wp-json/stat-analytics/v1/facebook-pixel’,
type: ‘POST’,
data: {
event_name: !eventName ? null : eventName,
parameters: !parameters ? {} : parameters,
source_url: window.location.href
},
success: function( data, textStatus, jqXHR ) {
//console.log( data );
},
error: function ( jqXHR, textStatus, errorThrown ) {
//console.log( jqXHR );
}
} );
};

jQuery( window ).on( ‘load’, function() {
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);

fbq( ‘init’, ‘436331036555416’ );
fbq( ‘track’, ‘PageView’ );

document.addEventListener( ‘stat-hubspot-signup-subscribed’, () => {
// Successful HubSpot newsletter signup AJAX form submission.
window.statGlobal.analytics.fbq( ‘Lead’ );
} );
window.statGlobal.analytics.fbq( ‘ViewContent’ );
} );

Source link

Share This Article
error: Content is protected !!